FY2025 · ended Dec 31, 2025 · Revenue $3.50M, +436.5% YoY · Filed Mar 5, 2026
CAMP4 Therapeutics Corporation (CAMP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.5 million and a net loss of $80.4 million. Free cash flow was -$29.8 million. As of Sep 30, 2026 it held $124.5 million in cash and investments and $6.5 million in total debt.
Revenue (TTM)
$5.32M
+54.1% vs year-ago TTM
Net income (TTM)
$-121.10M
-126.8% vs year-ago TTM
Operating cash flow (TTM)
$-25.54M
+45.8% vs year-ago TTM
Free cash flow (TTM)
$-26.41M
+44.6% vs year-ago TTM
EPS (TTM)
$-1.95
+22.7% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
51.92M
+157.5% vs prior year
Net cash
$118.07M
as of Sep 30, 2026
Operating margin
-1001.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CAMP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736730
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $3.5M | $652,000 |
| Operating income | -$52.6M | -$53.1M |
| Net income | -$80.4M | -$51.8M |
| Diluted EPS | -$2.65 | -$11.04 |
| Operating cash flow | -$29.6M | -$45.6M |
| Free cash flow | -$29.8M | -$46.0M |
| Total assets | $117.8M | $78.3M |
| Total liabilities | $70.1M | $15.2M |
| Stockholders' equity | $47.7M | $63.1M |
| Cash and investments | $109.5M | $64.0M |
| Total debt | $2.0M | $8.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K | Current report | Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 4, 2026 | Aug 3, 2026 |
All 192 CAMP4 Therapeutics Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.